By: iTopTopics Staff
Photo by U.S. Army Corps of Engineers Europe District, licensed under CC by 2.0
On August 3rd, 2016, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched the first phase of a clinical trial of a vaccine candidate intended to prevent Zika virus infection. That vaccine — dubbed ZPIV for purified inactivated Zika virus — uses a more traditional vaccine approach and depends on dead virus particles.
The 2nd phase of the trials could begin as early as January 2017.